Synflorix Eiropas Savienība - latviešu - EMA (European Medicines Agency)

synflorix

glaxosmithkline biologicals s.a. - pneumococcal polysaccharide serotype 23f, pneumococcal polysaccharide serotype 4, pneumococcal polysaccharide serotype 5, pneumococcal polysaccharide serotype 6b, pneumococcal polysaccharide serotype 7f, pneumococcal polysaccharide serotype 9v, pneumococcal polysaccharide serotype 1, pneumococcal polysaccharide serotype 14, pneumococcal polysaccharide serotype 18c, pneumococcal polysaccharide serotype 19f - pneumococcal infections; immunization - vakcīnas - aktīva imunizācija pret invazīvu slimību un akūtu vidusauss iekaisumu, ko izraisa streptococcus pneumoniae, zīdaiņiem un bērniem no sešām nedēļām līdz piecu gadu vecumam. skatīt nodaļas 4. 4 un 5. 1 informāciju par produktu par aizsardzību pret specifiskiem pneimokoku serotipiem. izmantot synflorix būtu jānosaka, pamatojoties uz oficiālajām rekomendācijām, ņemot vērā ietekmi invazīvās slimības dažādās vecuma grupās, kā arī mainīgumu serotipu epidemioloģiju dažādās ģeogrāfiskās teritorijās.

Physioneal 40 Glucose 1,36% w/v/13,6 mg/ml šķīdums peritoneālai dialīzei Latvija - latviešu - Zāļu valsts aģentūra

physioneal 40 glucose 1,36% w/v/13,6 mg/ml šķīdums peritoneālai dialīzei

baxter latvia, sia, latvia - glikozes monohydricum, kalcija chloridum, magnija chloridum, natrii chloridum, natrii lactas, natrii hydrogenocarbonas - Šķīdums peritoneālai dialīzei - 13,6 mg/ml

Dianeal PD4 Glucose 1,36% w/v/13,6 mg/ml šķīdums peritoneālai dialīzei Latvija - latviešu - Zāļu valsts aģentūra

dianeal pd4 glucose 1,36% w/v/13,6 mg/ml šķīdums peritoneālai dialīzei

baxter latvia, sia, latvia - glikozes monohydricum, magnija chloridum hexahydricum, kalcija chloridum dihydricum, natrii lactas, natrii chloridum - Šķīdums peritoneālai dialīzei - 13,6 mg/ml

Imbruvica Eiropas Savienība - latviešu - EMA (European Medicines Agency)

imbruvica

janssen-cilag international nv - ibrutinibs - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.